Insulin glargine, lixisenatide
Sold as Soliqua, Vivsuna
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 4
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Soliqua 33/100 EACH 1,0 ml SOLUTION CONTAINS: INSULIN GLARGINE 100,0 units LIXISENATIDE 33,0 μg | 33/100Solution for injection | 52014952/32.16/0149Approved 19 August 2024 | Registered | Not determined | PIPIL |
| Soliqua 50/100 EACH 1,0 ml SOLUTION CONTAINS: INSULIN GLARGINE 100,0 units LIXISENATIDE 50,0 μg | 50/100Solution for injection | 52015052/32.16/0150Approved 19 August 2024 | Registered | Not determined | PIPIL |
| Vivsuna 33/100 EACH 1,0 ml SOLUTION CONTAINS INSULIN GLARGINE 100,00 UNITS LIXISENATIDE 33,0 ug | 33/100 | 52015152/32.16/0151 | Cancelled | Not determined | None |
| Vivsuna 50/100 EACH 1,0 ml SOLUTION CONTAINS INSULIN GLARGINE 100,00 UNITS LIXISENATIDE 50,0 ug | 50/100 | 52015252/32.16/0152 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Lixisenatide
Consolidated Schedules 06 July 2026, line 6949
S3: Insulin glargine
Consolidated Schedules 06 July 2026, line 3800
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.